Pfizer's HYMPAVZI Receives FDA Priority Review for Blood Cancer Treatment

Pfizer Inc. (NYSE:PFE) is one of top healthcare stocks priced under $50 for investment. Pfizer Inc. (NYSE:PFE) stated on February 6 that the U.S. Food and Drug Administration has accepted and provided Priority Review for its supplemental Biologics License Application for HYMPAVZI® to broaden the approved indication to cover the treatment of hemophilia A or B patients aged 6 years and older with inhibitors, as well as pediatric patients with hemophilia A or B who do not have inhibitors. HYMPAVZI is currently approved in the United States for treating patients 12 years of age and older with hemophilia A who do not have factor VIII inhibitors, or hemophilia B who do not have factor IX inhibitors.

Pfizer Inc. (NYSE:PFE) also stated that the FDA has established a Prescription Drug User Fee Act action date for the second quarter of 2026. Should it be approved, HYMPAVZI would offer a blend of bleeding protection along with a simple, once-weekly subcutaneous injection method that involves little preparation and eliminates the necessity for regular treatment-related laboratory monitoring in these challenging patient groups.

In a separate update, Pfizer Inc. (NYSE:PFE) revealed on February 5 that it has initiated its TrumpRx program, aiming to increase access to and reduce the cost of innovative medications for U.S. residents. The program offers significant discounts on more than 30 medicines compared to their list prices. According to management, this effort is included in Pfizer Inc.'s (NYSE:PFE) larger landmark Most Favored Nation deal with the U.S. government.

Pfizer Inc. (NYSE:PFE) is a worldwide biopharmaceutical corporation engaged in the production, research, promotion, and distribution of biopharmaceutical products across the globe. It promotes health, prevention, therapy, and solutions in developing and emerging markets.

Although we recognize the potential for growth in PFE, we are more confident in the outlook for certain AI stocks that offer better prospects for higher returns with lower risk. If you're seeking an AI stock that is more promising than PFE and has the potential for 100x gains, review our report on this topic.cheapest AI stock.

READ NEXT: 30 Stocks That Have the Potential to Double in Three Years and 11 Secret AI Stocks That Are Worth Purchasing Today.

Disclaimer: None. This article was first published atInsider Monkey.